A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
A phase 2 trial of Disitamab vedotin in non-small-cell lung cancer, ovarian cancer, endometrial cancer and head and neck squamous cell carcinoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Overview
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 is a phase 2 interventional study registered as NCT06003231 by Seagen, a wholly owned subsidiary of Pfizer, with 120 participants enrolled, started 2023-11-14 and due to reach its primary completion in 2026-03-27. Interventions recorded: disitamab vedotin.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of GV20-0251 in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.